Home / Market News / $IGC
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1

Nov 18, 2026, 2:17 PM UTC · Primary ticker $IGC

IGC Pharma announced the completion of patient dosing in its Phase 2 CALMA trial for IGC-AD1, a cannabinoid-based treatment for Alzheimer's agitation. This marks a significant step towards data analysis and potential future development, creating moderate positive sentiment for the company as it progresses through clinical trials.

IGC Pharma has completed patient dosing in its Phase 2 CALMA trial for IGC-AD1, a cannabinoid-based formulation targeting agitation in Alzheimer's dementia. This milestone signifies the end of the active treatment phase, moving the company closer to data analysis and the potential release of trial results. For IGC, this is a positive development as it indicates progress in its clinical pipeline, which is crucial for biotech and pharmaceutical companies. The short-term implication is a potential uptick in investor confidence due to the advancement of a key drug candidate. Long-term, successful trial results could significantly boost the company's valuation and market position in neurodegenerative disorders. The key opportunity for traders lies in anticipating the data readout, as positive results could lead to substantial stock appreciation, while negative results would pose a significant risk.

$IGC positive Progress in key clinical trial
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.